- Home
- HFBL vs GANX Comparison
HFBL vs GANX Comparison
Compare HFBL & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFBL | GANX |
|---|---|---|
| Founded | 1924 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.2M | 74.6M |
| IPO Year | 2010 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HFBL | GANX |
|---|---|---|
| Price | $23.98 | $2.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 5.0K | ★ 529.9K |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | ★ 2.83% | N/A |
| EPS Growth | 7.69 | ★ 31.46 |
| EPS | ★ 1.55 | N/A |
| Revenue | ★ $1,303,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $15.49 | ★ N/A |
| Revenue Growth | ★ 17.49 | N/A |
| 52 Week Low | $13.03 | $1.53 |
| 52 Week High | $24.01 | $4.34 |
Technical Indicators
Market Signals| Indicator | HFBL | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 67.91 | 66.16 |
| Support Level | $21.08 | $1.65 |
| Resistance Level | N/A | $2.22 |
| Average True Range (ATR) | 0.58 | 0.13 |
| MACD | 0.04 | 0.05 |
| Stochastic Oscillator | 98.99 | 67.61 |
Price Performance
Historical ComparisonAbout HFBL Home Federal Bancorp Inc. of Louisiana
Home Federal Bancorp Inc of louisiana operates as a bank holding company. It is a federally chartered stock savings bank, which provides financial services to individuals, corporate entities, and other organizations. Its core activities consist of attracting deposits from the general public and using those funds to originate loans to the residential, commercial and multi-family segments. The company also invests securities held-to-maturity and securities available for sale.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.